Titan Pharmaceuticals, Inc. (OTCBB:TTNP) Tries to Return to $1

As the end of 2013 is in sight, Titan Pharmaceuticals, Inc. (OTCBB:TTNP) seems headed to repeating its feat from the end of last year, where after a long stagnant period the ticker exploded and regained its value. Now, TTNP is eying the $1 levels, while it drifted around 40 cents for a while. We expect renewed interest as the date for an FDA meeting in mid-November approaches.

Now, TTNP has the challenge to double in price, in order to bridge the gap from May, where the end of a promotion coincided with a negative-sounding statement from the FDA, which led to a 75% loss in a couple of days.

Still, TTNP is not guaranteed the good run- the company has yet to come with encouraging press releases, and as usual, the enthusiasm may be too much, and cause another disaster. At least those are the moods that message boards point to.

Now, the new week will show if the winning trend perseveres for TTNP, given the high expectations on message boards at the end of last week. Today is the deadline for submitting the application for the upcoming FDA meeting, so an update and an official announcement could further boost the attention given to TTNP. The longer-term prognosis for the shares is $5, if the Probruphine treatment receives a green light, potentially increasing the earnings.

But the implantation device offered by TTNP showed flaws that the FDA could not accept, and so the anti-opioid drug delivery system failed, awaiting another round. TTNP would have to also show how it has improved on its therapy.

For other pharmaceutical stocks, climbs still end up badly. Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) jumped more than double from 3 to 7 cents, but has been sliding in the past days, looking more chaotic as the enthusiasm split into opposing market forces.

And if you are looking for a success story, Soligenix, Inc. (OTBB:SNGX) is a fine example. The company received more than $34 million in funding for R&D activities, but nevertheless, it has slid from a peak at $2.40 toward $2.10.

TTNP has the hope of becoming a leader in the anti-addiction treatments. The company may benefit from the doctrine of the FDA to ease the way for companies that offer solutions to socially significant problems. Still, TTNP has many days to wonder and choose a direction. It is best to decide on your preferred time frame, and not rely too much on a good outcome, when just as easily TTNP could retreat.